NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies
After Temporary Pause Due to COVID-19 Pandemic

On May 18, 2020 NuCana plc (NASDAQ: NCNA) reported it has re-commenced enrollment of new patients in multiple clinical studies following the temporary pause necessitated by the COVID-19 pandemic (Press release, Nucana BioPharmaceuticals, MAY 18, 2020, View Source [SID1234558222]). NuCana previously announced the re-opening of its global Phase III study of Acelarin plus cisplatin in patients with biliary tract cancer (NuTide:121) on May 5, 2020. NuCana has now also re-opened the Phase I and Phase Ib clinical studies of NUC-3373 and the Phase I clinical study of NUC-7738.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"All of our clinical studies have now re-opened to new patient enrollment and we are pleased to be treating once again new patients who may benefit from our ProTides" said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. "The COVID-19 pandemic has had a dramatic impact on the global healthcare delivery system and advancing clinical studies of potential new treatments for cancer patients is of critical importance to NuCana."

The following clinical studies have re-opened to new-patient enrollment:

NuTide:121, the Phase III study of Acelarin (NUC-1031) plus cisplatin in patients with biliary tract cancer. The re-opening of NuTide:121 has begun in certain geographies including Australia, Canada, South Korea, Taiwan, Ukraine and the United Kingdom.

NuTide:302, the Phase Ib study of NUC-3373 in combination with other agents typically combined with 5-fluorouacil (5-FU) in patients with advanced colorectal cancer. The re-opening of NuTide:302 has begun in the United Kingdom.

NuTide:301, the Phase I clinical study of NUC-3373 in patients with advanced solid tumors.

NuTide:701, the Phase I clinical study of NUC-7738 in patients with advanced solid tumors.